Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer
Crossref DOI link: https://0-doi-org.brum.beds.ac.uk/10.1186/s12967-016-1037-z
Published Online: 2016-09-29
Published Print: 2016-12
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/springer_crossmark_policy
Eriksson, Emma
Wenthe, Jessica
Irenaeus, Sandra
Loskog, Angelica
Ullenhag, Gustav
Funding for this research was provided by:
the Swedish Cancer Society
the Swedish State Support
Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond
Lion's Cancer Fund
Lokon Pharma AB